## FINAL AGENDA
Center Outcomes Forum
WebEx
Friday, November 20, 2020; 11:00 AM – 3:30 PM CDT

<table>
<thead>
<tr>
<th>Time</th>
<th>Min</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:10</td>
<td>10</td>
<td>Welcome and Introductions</td>
<td>J. Douglas Rizzo, MD, MS</td>
</tr>
</tbody>
</table>
| 11:10 – 12:10 | 60  | Is minimal residual disease (MRD) for acute leukemia (AML, ALL) ready for use as a risk adjustment factor in the CSA?  
                             ▫ If not, what criteria need to be met in the future (e.g., consistent/standardized measures, etc.)?  
                             ▫ What changes in data collection should CIBMTR make to support future use of MRD? | Daniel Weisdorf, MD*  
                                           Stella M. Davies, MBBS, PhD, MRCP^  
                                           Chris Hourigan, DM, DPhil^  
                                           Selina Luger, MD^  
                                           Wael Saber, MD, MS^  
                                           Bart Scott, MD^ |
| 12:10 – 12:20 | 10  | Break                                                               |                                                  |
| 12:20 – 1:20 | 60  | Are there new approaches to account for social determinants of health in the CSA risk adjustment model? | Navneet Majhail, MD, MS*  
                                           Kira Bona, MD, MPH^  
                                           Luciano Costa, MD, PhD^  
                                           Terri Hahn, PhD^  
                                           Richard Maziarz, MD^  
                                           Tatenda Mupfudze, PhD^  
                                           Ron Potts, MD^ |
<p>| 1:20 – 1:40  | 20  | Break                                                               |                                                  |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Min</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 1:40 – 2:40  | 60  | Can CIBMTR adequately adjust for the impact of the COVID-19 pandemic in the CSA?  
- What factors are most essential and how can they be incorporated in the risk adjustment? | John Wingard, MD*  
Kwang Woo Ang, PhD^  
Christopher Dandoy, MD^  
Miguel Perales, MD^  
Bill Wood, MD, MPH^ |
| 2:40 – 2:50  | 10  | Break                                                                |                                                                                                   |
| 2:50 – 3:10  | 20  | CSA research project proposals (brief summary and plans)              | Wael Saber, MD, MS  
Akshay Sharma, MD  
Leslie Lehmann, MD  
Mark Juckett, MD, MHCM |
| 3:10 – 3:30  | 20  | Update on consequences of CSA public reporting                        | Navneet Majhail, MD, MS  
J. Douglas Rizzo, MD, MS |

*Moderator  ^Panelist